Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
Revolution Medicines (RVMD) Stock Price & Analysis
236 Followers
RVMD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.44 - $48.61
Previous Close$46.14
Volume1.15M
Average Volume (3M)1.51M
Market Cap
$7.61B
Enterprise Value$6.00B
Total Cash (Recent Filing)$1.70B
Total Debt (Recent Filing)$88.03M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Aug 06, 2024EPS Estimate
-$0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.76
Shares Outstanding164,986,227
10 Day Avg. Volume1,265,895
30 Day Avg. Volume1,508,137
Standard Deviation0.17
R-Squared0.21
Alpha-0.00077
Financial Highlights & Ratios
Price to Book (P/B)3.59
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-13.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.31K
Enterprise Value/Gross Profit517.87
Enterprise Value/Ebitda-12.47
Forecast
1Y Price Target
$56.64Price Target Upside22.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Revolution Medicines News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe 8.1 months of median progression-free survival in 2L PDAC surpassed expectations and indicates strong efficacy.
FinancialsUpdated guidance including $1.7B cash position is projected to provide runway into 2027, covering the next slew of pipeline updates.
Market ReactionShares were up on the back of what analysts characterize as a best-case readout for RMC-6236 in PDAC patients.
Bears Say
Clinical EfficacyThe median progression-free survival for 3L+ PDAC falls into the lower end of the expected range, potentially underestimating the survival benefit.
Regulatory And Market RisksRisks include clinical setbacks with RMC-4630, inability to secure timely regulatory approval, poorer-than-anticipated sales performance, failures with other pipeline candidates, and possible long-term dilution risk.
Side EffectsEmerging side effect issues such as large intestine perforation could impact progression-free survival.
---
Ownership Overview
20.79% Insiders
25.96% Mutual Funds
15.16% Other Institutional Investors
38.10% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RVMD FAQ
What was Revolution Medicines’s price range in the past 12 months?
Revolution Medicines lowest stock price was $15.44 and its highest was $48.61 in the past 12 months.
What is Revolution Medicines’s market cap?
Currently, no data Available
When is Revolution Medicines’s upcoming earnings report date?
Revolution Medicines’s upcoming earnings report date is Aug 06, 2024 which is in 15 days.
How were Revolution Medicines’s earnings last quarter?
Revolution Medicines released its earnings results on May 08, 2024. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$0.746 by $0.046.
Is Revolution Medicines overvalued?
According to Wall Street analysts Revolution Medicines’s price is currently Undervalued.
Does Revolution Medicines pay dividends?
Revolution Medicines does not currently pay dividends.
What is Revolution Medicines’s EPS estimate?
Revolution Medicines’s EPS estimate is -$0.78.
How many shares outstanding does Revolution Medicines have?
Revolution Medicines has 164,986,220 shares outstanding.
What happened to Revolution Medicines’s price movement after its last earnings report?
Revolution Medicines reported an EPS of -$0.7 in its last earnings report, beating expectations of -$0.746. Following the earnings report the stock price went down -2.245%.
Which hedge fund is a major shareholder of Revolution Medicines?
Among the largest hedge funds holding Revolution Medicines’s share is Baker Bros Advisors LP. It holds Revolution Medicines’s shares valued at 243M.
---
Revolution Medicines Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.64 (22.76% Upside)
$56.64 (22.76% Upside)
Blogger Sentiment
Bullish
RVMD Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 3.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.76%
12-Months-Change
Fundamentals
Return on Equity
-36.17%
Trailing 12-Months
Asset Growth
77.81%
Trailing 12-Months
Company Description
Revolution Medicines
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
---
RVMD Earnings Call
Q1 2024
0:00 / 0:00
---
RVMD Stock 12 Month Forecast
Average Price Target
$56.64
▲(22.76% Upside)
Technical Analysis
Crispr Therapeutics AG
―
Meiragtx Holdings
―
Amneal Pharmaceuticals
―
Fate Therapeutics
―
Best Analysts Covering RVMD
1 Year
1 Year Success Rate
10/10 ratings generated profit
1 Year Average Return
+39.19%
reiterated a buy rating 7 days ago
Copying Benjamin Burnett's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +39.19% per trade.
---